Peter Mazal

Medical University of Vienna — Austria

Medicine · Health Sciences

29h-index3.2kcitations103works1.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(17), Neuroendocrine Tumor Research Advances(16), Lung Cancer Research Studies(12), Radiopharmaceutical Chemistry and Applications(11), Neuroblastoma Research and Treatments(9)

Publications103 total

PSMA-Directed PET/MRI Enables Noninvasive Diagnosis and Prognosis in Patients with Increased PSA Levels: Results from the Prospective Randomized RAPID Trial
Journal of Nuclear Medicine·2025
Comparisons of treatment performance and therapy sequences in neuroendocrine neoplasms using progression-free survival ratios
European Journal of Nuclear Medicine and Molecular Imaging·2025Open Access
Methylation Profiles Differ According to Clinical Characteristics in Well-Differentiated Neuroendocrine Tumors of the Lung
Endocrine Pathology·2025Open Access
Patterns and outcomes of current antitumor therapy for high-grade neuroendocrine neoplasms: perspective of a tertiary referral center
Journal of Cancer Research and Clinical Oncology·2025· 2 citedOpen Access
Liver metastases in high‐grade neuroendocrine neoplasms: A comparative study of hepatic tumor volume and biochemical findings in <scp>NET</scp> <scp>G3</scp> versus <scp>NEC</scp>
Journal of Neuroendocrinology·2024· 1 citedOpen Access
Long-term experience with octreotide and lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors
Clinical & Translational Oncology·2024· 4 citedOpen Access
1161P Progression-free survival ratio and the implications for treatment sequencing in neuroendocrine neoplasms
Annals of Oncology·2024Open Access
Metastatic disease and major adverse cardiovascular events preceding diagnosis are the main determinants of disease-specific survival of pheochromocytoma/paraganglioma: long-term follow-up of 303 patients
Frontiers in Endocrinology·2024· 8 citedOpen Access
Author response for "Liver metastases in high‐grade neuroendocrine neoplasms: A comparative study of hepatic tumor volume and biochemical findings in &lt;scp&gt;NET&lt;/scp&gt;&lt;scp&gt;G3&lt;/scp&gt; versus &lt;scp&gt;NEC&lt;/scp&gt;"
2024
NEC versus NET G3—is there a grey zone? Case report of pancreatic NET G3 with rapid disease progression
memo - Magazine of European Medical Oncology·2024· 2 citedOpen Access
Syndromic MEN1 parathyroid adenomas consist of both subclonal nodules and clonally independent tumors
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin·2024· 2 citedOpen Access
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms
Endocrine Related Cancer·2024· 1 cited
From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms
Therapeutic Advances in Medical Oncology·2024· 5 citedOpen Access
Does the dose matter? Antiproliferative efficacy and toxicity of everolimus in patients with neuroendocrine tumors – Experiences from a tertiary referral center
Journal of Neuroendocrinology·2023· 7 cited
Data from PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact
2023Open Access
Supplementary Data from PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact
2023Open Access
Supplementary Data from PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact
2023Open Access
Data from PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact
2023Open Access
Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study
The Lancet Oncology·2023· 64 citedOpen Access
Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice
ESMO Open·2022· 13 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Martin Susani(17), Andrea Haitel(12), Herbert Budka(9), Johannes A. Hainfellner(7), Alexander Haug(4), Marcus Hacker(4), Markus Hartenbach(4), Christine Haberler(3), Lukas Kenner(3), Bernhard Grubmüller(3), Pascal Baltzer(3), Sabrina Hartenbach(3), Wolfgang Wadsak(3), Gero Kramer(3), Shahrokh F. Shariat(3), Anke Koller(3), Michael Marberger(3), Fritz Wrba(3), Roland Sedivy(3), Ludwig Wagner(3)